AI
REGN icon

Atom Investors’s Regeneron Pharmaceuticals REGN Stock Holding History

Atom Investors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-259
Closed -$272K – 613
2024
Q3 		$272K Sell
259
-26
-9% -$28.9K 0.03% 391
2024
Q2 		$300K Sell
285
-2,012
-88% -$1.95M 0.03% 376
2024
Q1 		$2.21M Buy
+2,297
New +$2.18M 0.28% 113
2023
Q2 		– Sell
-278
Closed -$228K – 360
2023
Q1 		$228K Buy
+278
New +$210K 0.12% 188

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Atom Investors's REGN Position: Q4 2024 in Review

Atom Investors sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 259 shares — an estimated $272K sold.

Atom Investors first reported a position in REGN in Q1 2023 and held it in 4 quarters. The position peaked at $2.21M in Q1 2024. 1,317 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

  • Atom Investors reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Atom Investors sold 259 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $272K.
  • Atom Investors first reported a position in Regeneron Pharmaceuticals in Q1 2023 and held it in 4 quarters.
  • Atom Investors's Regeneron Pharmaceuticals position peaked at $2.21M in Q1 2024.
  • 1,317 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Atom Investors's 13F filing for Q4 2024, filed 14 Feb 2025.